Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE.

Rationale: Follow-up of patients with emphysema treated with endobronchial valves is limited to 3-12 months after treatment in prior reports. To date, no comparative data exist between treatment and control subjects with a longer follow-up. Objectives: To assess the durability of the Spiration Valve System (SVS) in patients with severe heterogeneous emphysema over a 24-month period. Methods: EMPROVE, a multicenter randomized controlled trial, presents a rigorous comparison between treatment and control groups for up to 24 months. Lung function, respiratory symptoms, and quality-of-life (QOL) measures were assessed. Results: A significant improvement in forced expiratory volume in 1 second was maintained at 24 months in the SVS treatment group versus the control group. Similarly, significant improvements were maintained in several QOL measures, including the St. George's Respiratory Questionnaire and the COPD Assessment Test. Patients in the SVS treatment group experienced significantly less dyspnea than those in the control group, as indicated by the modified Medical Research Council dyspnea scale score. Adverse events at 24 months did not significantly differ between the SVS treatment and control groups. Acute chronic obstructive pulmonary disease exacerbation rates in the SVS treatment and control groups were 13.7% (14 of 102) and 15.6% (7 of 45), respectively. Pneumothorax rates in the SVS treatment and control groups were 1.0% (1 of 102) and 0.0% (0 of 45), respectively. Conclusions: SVS treatment resulted in statistically significant and clinically meaningful durable improvements in lung function, respiratory symptoms, and QOL, as well as a statistically significant reduction in dyspnea, for at least 24 months while maintaining an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT01812447).

Thrombocytopenia in the intensive care unit.

Thrombocytopenia is a common laboratory finding in critically ill patients admitted to the intensive care unit. Potential etiologies of thrombocytopenia are myriad, ranging from acute disease processes and concomitant conditions to exposures and drugs. The mechanism of decreased platelet counts can also be varied: laboratory measurement may be spurious, platelet production may be decreased, or platelet destruction or sequestration may be increased. In addition to evaluation for the cause of thrombocytopenia, the clinician must also guard against spontaneous bleeding due to thrombocytopenia, prophylax against bleeding resulting from an invasive procedure performed in the setting of thrombocytopenia, and treat active bleeding related to thrombocytopenia.

Toxic inhalational exposures.

Respirable toxicants are a spectrum of irritant and nonirritant gases, vapors, fumes, and airborne particles that can be entrained into the body through the respiratory tract, resulting in exposures that cause pulmonary injury and/or systemic disease. Sources of respirable toxicants include structural fires, industrial accidents, domestic mishaps, and intentional releases of injurious agents on the battleground (warfare) or in civilian settings (acts of terrorism). Acute toxic inhalational exposures may result in respiratory failure, multisystem organ dysfunction, and death. Management of victims includes assessment and protection of the airway, monitoring and treatment of systemic toxicity, and delivery of exposure-specific and nonspecific therapies that improve outcomes. Treatments may include antidotes, hyperbaric oxygen, and other nonspecific life-supporting interventions.

Evaluation of patients with small, subcentimeter nodules.

The prevalence of subcentimeter pulmonary nodules is on the rise due to widespread use of multidetector row computed tomography. These lesions have created a new set of challenges for patients and their physicians. Such nodules are poorly characterized by imaging tests and are difficult to biopsy. Fortunately, the available data suggest that the vast majority of such nodules are benign in etiology. However, this increases the challenge to provide a cost-effective evaluation that minimizes unnecessary radiation exposure and complications from invasive biopsies while promptly identifying malignancy when it is present. In this review, we summarize the current available literature regarding subcentimeter nodules, as well as the current recommendations regarding their investigation.

Outdoor air pollution: overview and historical perspective.

Outdoor air pollution is a significant public health hazard in population centers throughout the world. Recognition of air pollution as a nuisance dates back many centuries. Decades of research have established a strong link between air pollution and a spectrum of adverse health effects. Health care practitioners rarely consider the health risk of air pollution in the course of patient care and generally do not provide risk modification strategies as part of patient management. The purpose of this article is to provide front line clinicians with: 1) an overview of the evolution in scientific understanding about air pollution and its health effects, 2) an introduction to the hazards contemporary air pollution presents to patients, and 3) an introduction to the contributions of specific pollutants to outdoor air quality.

Outdoor air pollution: particulate matter health effects.

Numerous investigations studying multiple populations across a variety of environmental settings have demonstrated a strong association between ambient air particulate matter and cardiopulmonary morbidity and mortality. In most studies, the effect size of ambient air particulate pollution on health outcomes is small. However, the exposed population worldwide is very large. Accordingly, particulate air pollution appears to be an important public health hazard that makes an important contribution to the total burden of disease and death in populations across the world. Much of the evidence linking ambient air particulates with adverse health effects is derived from population-based, observational research with potential unidentified confounding exposures, precluding definitive assessments about causation and providing limited mechanistic insights. A growing body of research suggests particulate-associated adverse health effects result from the induction of proinflammatory responses in the lower respiratory tract. Ambient air particulates may increase lung cancer risk.

Outdoor air pollution: ozone health effects.

Ozone is a respiratory irritant associated with a spectrum of adverse health events. Ground-level ozone has been shown to cause decreases in lung function and has been associated with other important respiratory health effects. Some reports suggest short-term increases in ozone lead to increased cardiopulmonary mortality. Other studies have found no association between exposure and measured health effects. Outdoor air pollution consists of multiple copollutant exposures complicating definitive assessments about ambient air ozone exposure-effect relations.

Outdoor air pollution: nitrogen dioxide, sulfur dioxide, and carbon monoxide health effects.

Nitrogen dioxide (NO2), sulfur dioxide (SO2), and carbon monoxide are important ambient air pollutants. High-intensity, confined space exposure to NO2 has caused catastrophic injury to humans, including death. Ambient NO2 exposure may increase the risk of respiratory tract infections through the pollutant's interaction with the immune system. Sulfur dioxide (SO2) contributes to respiratory symptoms in both healthy patients and those with underlying pulmonary disease. Controlled human exposure studies have demonstrated that experimental SO2 exposure causes changes in airway physiology, including increased airways resistance. Both acute and chronic exposure to carbon monoxide are associated with increased risk for adverse cardiopulmonary events, including death. However, studies have not demonstrated a clear dose-dependent health risk response to increasing amounts of these pollutants except at high concentrations. In addition, a number of studies examining the effects of ambient level exposure to NO2, SO2, and CO have failed to find associations with adverse health outcomes.

Outdoor air pollution: counseling and exposure risk reduction.

Air pollution is monitored on a daily basis in large population centers in the United States and reported to the general public through a variety of media outlets as the Air Quality Index. This index is based on current national air quality standards for criteria air pollutants established by the US Environmental Protection Agency. Patients at increased risk for adverse effects of inhaled air pollutants include those who have been diagnosed with chronic lung disease and cardiovascular disease, including asthma, chronic obstructive pulmonary disease, coronary artery disease, congestive heart failure, and peripheral vascular disease, although others may also be at risk during periods of unusually high pollutant levels. These patients should be educated regarding what symptoms may be related to poor air quality and how they can monitor the Air Quality Index to modify their activity to prevent symptoms and other adverse events. Heavy outdoor exertion should be avoided on days expected to have poor air quality, or performed earlier in the day on days when outdoor activity cannot be avoided. We recommend advising patients in clear, strong, personalized language that air pollution is harmful and that persons with cardiopulmonary disease are at elevated risk of experiencing a serious adverse health effect from exposure.

Recurrence of pulmonary intravascular bronchoalveolar tumor with mediastinal metastasis 20 years later.

Pulmonary intravascular bronchoalveolar tumor (IVBAT) also recognized as pulmonary epithelioid hemangioendothelioma, is a rare malignant vascular tumor of unknown etiology. IVBAT is a tumor of multicentric origin and the lungs are rarely involved, with only about 60 cases of pulmonary IVBAT described in the literature. The prognosis is unpredictable, with life expectancy ranging from 1 to 15 years. We report an unusual case of pulmonary IVBAT that recurred in the lung with metastasis to the mediastinum.